In addition to radiomics, some scholars have also tested the RNA expression level of patients with relapsed NSCLC who received PD1/PD-L1 treatment and used the obtained genome to use machine learning to perform feature selection and establish a prediction model to accurately predict whether the patient is suitable for anti-PDL-1 treatment (55). This evidence concerns the gene CD274 and non-small cell lung carcinoma.